Almirall s solid core business Q1 performance boosted by growth drivers momentum 10 May 2021 Good business performance with significant growth in Core EBITDA: Core Net Sales €215.4 MM (+5% year-on-year) and Core EBITDA €68.0MM (+46% year-on-year). Growth drivers momentum continues. Ilumetri® sales growing c.+90% year-on-year, Klisyri® launched successfully in the US in February 2021 and Seysara® modest rebound in line with the overall OAB market. Gianfranco Nazzi joined as Almirall s new CEO on May 1st, 2021. His international experience and expertise in executing product launches will enable the company to deliver its global strategy and carry on the strategic roadmap. Innovative pipeline with significant value still to be unlocked: expected upcoming approvals of Klisyri® and Wynzora® in Europe in Q2 2021, and lebrikizumab phase 3 ongoing with headline readout expected in H2 2021.
Reig Jofre expands into Polish pharma sector
REIG JOFRE, a pharmaceutical company listed on the Spanish Stock Exchange, continues its drive for international expansion with the creation of the company REIG JOFRE Sp. z o.o. in Poland.
Its pharmaceutical market accounts for around 9 billion euros and has an annual growth rate of above 5%, where the company already has a presence through distribution agreements.
The company in Poland will have a marketing team and own sales network specialized in the pharmaceutical market. Initially, the aim is to meet the demand for pharmaceutical products indicated for the treatment of osteoarthritis and osteoarticular pain by the Specialty Pharmacare division, and gradually, to introduce products from dermatology line and the Consumer Healthcare ranges (weight control, energy, stress and sleep products, and beauty care).
Share this article
Share this article
BARCELONA, Spain, April 28, 2021 /PRNewswire/ Grifols (MCE: GRF, MCE: GRF.P, andNASDAQ: GRFS), a leading global producer of plasma-derived medicines with a history of more than 110 years contributing to improve the health and well-being of people, today announced it has signed an agreement with the government of Andorra through Andorra Development and Investment (ADI) to establish a global R+D+i hub to advance knowledge of the human immune system and investigate and develop new immune therapies.
Pyrenees Immunology Research Center (PYIRC)
Innovation 1
Pyrenees Immunology Research Center (PYIRC)
The planned facility, the Pyrenees Immunology Research Center (PYIRC), will focus on developing treatments for immune system disorders that can result in diseases including autoimmunity disorders, cancer and emerging infectious diseases. It will also host and sponsor conferences, symposiums and educational programming on the subject matter as wel
Grifols and Andorran government will establish world-class immunology research hub to expand global knowledge of the immune system and develop therapeutics biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.